Nerves keep pancreatic cancer cells from starving, study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers found that pancreatic cancer cells avert starvation by signaling to nerves, which grow deeply into dense tumors and secrete nutrients.

The study, based on experiments in cancer cells, mice, and human tissue samples, was published Nov. 2 in Cell.

The study addresses pancreatic ductal adenocarcinoma, the deadliest cancer of the pancreas with a five-year survival rate below 10%. Such tumors encourage the growth of dense tissue that presses on blood vessels, reducing the supply of blood-borne nutrients like serine. This amino acid is used as a building block for proteins, and is required for cancer cells to multiply.

Led by researchers from NYU Grossman School of Medicine, the Department of Radiation Oncology at NYU Langone Health, and Perlmutter Cancer Center, the study found that starving pancreatic cancer cells secrete a protein called nerve growth factor, which sends signals to extensions of nerve cells, instructing them to grow deeply into tumors.

The researchers found further that such extensions, called axons, secrete serine, which rescues pancreatic cancer cells from starvation and restores their growth.

“Our study offers more proof that pancreatic cancers are remarkable metabolic scavengers, which contributes to their deadliness,” corresponding author Alec Kimmelman,the Anita Steckler and Joseph Steckler Chair of the Department of Radiation Oncology at NYU Langone, said in a statement. “The ability of nerves to funnel nutrients from the bloodstream to the more austere pancreatic tumor microenvironment is a fascinating adaptation, and could lead to therapeutic approaches that interfere with this unique flexibility.”

The study found that pancreatic cancer cells starved of serine take advantage of the process by which messenger RNA strands are translated into proteins. Bases of mRNA molecular strands are decoded into amino acids using three-base units called codons.

Ribosomes read each codon as they link amino acids together in the right order, but ribosomes stall if there is a lack of available amino acids.

The researchers found that serine-starved pancreatic cancer cells more significantly slow the rate at which two of the six serine codons (TCC and TCT), but not all six as assumed, are translated into amino acid chains.

Under serine-starved situations, this variability lets cancer cells minimize the production of certain proteins, but continue to build stress-adaptive proteins like nerve growth factor, which happens to be encoded by few TCC and TCT codons.

NGF and other factors are known to encourage nerves to grow into pancreatic tumors, and to increase tumor growth as well. The study is the first to show that axons, extensions of neuronal cells that transmit their signals, provide metabolic support to cancer cells by secreting serine in nutrient-deprived areas.

In a glimpse of potential future applications for the study, mice with PDAC tumors fed serine-free diets saw 50% slower tumor growth. To go beyond what diet alone could achieve, the researchers also blocked the recruitment of axons into PDAC tumors using FDA-approved LOXO-101. The drug blocks the activation of a receptor protein on the surface of neurons that interacts with nerve growth factor (also called TRK-A), thereby inhibiting the ability of neurons to send their axons into tumors.

LOXO-101 alone did not slow PDAC tumor growth in mice, but slowed it by an additional 50% when combined with a serine-free diet, compared with the diet alone. This suggests that nerves were necessary to support PDAC cell growth in serine-deprived tumor regions.

“As TRK inhibitors are approved in the treatment of some cancers, they might have value in combination with a low serine diet following surgery in the perhaps 40% of patients with PDAC tumors that can’t make serine,” lead study author Robert Banh, a post-doctoral scholar in Kimmelman’s lab, said in a statement. “Whether this approach could decrease tumor recurrence by limiting the nutrient supply would need to be confirmed in clinical trials.”

YOU MAY BE INTERESTED IN

Companies vying for accelerated approval and devising strategies for confirmatory trials would be best served by seeking prospective sign-off from FDA, agency officials say.  Officials from the FDA Oncology Center of Excellence described these best practices in a perspective piece in the Sept. 21 issue of The New England Journal of Medicine and discussed the...

Login